[go: up one dir, main page]

MX342912B - Aplicaciones antibacterianas de nanofibras de poli-n-acetilglucosamina. - Google Patents

Aplicaciones antibacterianas de nanofibras de poli-n-acetilglucosamina.

Info

Publication number
MX342912B
MX342912B MX2012011816A MX2012011816A MX342912B MX 342912 B MX342912 B MX 342912B MX 2012011816 A MX2012011816 A MX 2012011816A MX 2012011816 A MX2012011816 A MX 2012011816A MX 342912 B MX342912 B MX 342912B
Authority
MX
Mexico
Prior art keywords
poly
compositions
acetylglucosamine
bacterial
bacterial applications
Prior art date
Application number
MX2012011816A
Other languages
English (en)
Other versions
MX2012011816A (es
Inventor
N Vournakis John
Finkielsztein Sergio
Original Assignee
Marine Polymer Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marine Polymer Tech Inc filed Critical Marine Polymer Tech Inc
Publication of MX2012011816A publication Critical patent/MX2012011816A/es
Publication of MX342912B publication Critical patent/MX342912B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen en la presente composiciones que comprenden fibras acortadas de poli-N-acetilglucosamina y/o un derivado de las mismas ("nanofibras de sNAG") y aplicaciones antibacterianas de tales composiciones. Las nanofibras de sNAG pueden formularse en composiciones para la prevención y/o tratamiento de infecciones bacterianas y enfermedades asociadas con tales infecciones. También se describen regímenes que emplean tales composiciones.
MX2012011816A 2010-04-15 2011-04-15 Aplicaciones antibacterianas de nanofibras de poli-n-acetilglucosamina. MX342912B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32465710P 2010-04-15 2010-04-15
PCT/US2011/032709 WO2011130646A1 (en) 2010-04-15 2011-04-15 Anti-bacterial applications of poly -n-acetylglucosamine nanofibers

Publications (2)

Publication Number Publication Date
MX2012011816A MX2012011816A (es) 2013-01-22
MX342912B true MX342912B (es) 2016-10-19

Family

ID=44799052

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012011816A MX342912B (es) 2010-04-15 2011-04-15 Aplicaciones antibacterianas de nanofibras de poli-n-acetilglucosamina.

Country Status (13)

Country Link
US (5) US8858964B2 (es)
EP (1) EP2563371A4 (es)
JP (3) JP2013523898A (es)
KR (1) KR101883797B1 (es)
CN (2) CN103108638B (es)
AU (1) AU2011239466B2 (es)
BR (1) BR112012025844A2 (es)
CA (1) CA2796068C (es)
HK (1) HK1185278A1 (es)
IL (1) IL222375A (es)
MX (1) MX342912B (es)
NZ (2) NZ602909A (es)
WO (1) WO2011130646A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2121048T3 (en) 2007-02-19 2015-11-23 Marinepolymer Tech Inc Hemostatic compositions and therapeutic regimens
MX342912B (es) 2010-04-15 2016-10-19 Marine Polymer Tech Inc Aplicaciones antibacterianas de nanofibras de poli-n-acetilglucosamina.
CN107412256A (zh) 2011-04-15 2017-12-01 海洋聚合物技术公司 用聚‑n‑乙酰基葡糖胺纳米纤维治疗疾病
WO2013049648A1 (en) * 2011-09-30 2013-04-04 David Hains Compositions and methods for detection of defensins in a patient sample
WO2013174832A1 (en) * 2012-05-22 2013-11-28 Novartis Ag Meningococcus serogroup x conjugate
WO2013192157A1 (en) * 2012-06-18 2013-12-27 Duke University Non-human model for wound healing
JP6243443B2 (ja) 2012-12-20 2017-12-06 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 全身健康状態の尺度としてのパターン認識受容体の発現
AU2014248454B2 (en) 2013-03-14 2018-11-15 Marine Polymer Technologies, Inc. Treatment of disease with poly-N-acetylglucosamine nanofibers
JP2015048436A (ja) * 2013-09-03 2015-03-16 公立大学法人福井県立大学 植物の耐病性を向上させる、生物由来キチン質含有物、その使用方法、及びその製造方法
EP3034612A1 (en) 2014-12-16 2016-06-22 Greenaltech, S.L. Chitin and chitosan producing methods
US10500222B2 (en) * 2015-10-19 2019-12-10 Wayne State University Compositions and methods relating to treatment of infection
CN107460140B (zh) * 2016-06-02 2020-11-13 浙江科技学院 一种芽孢杆菌hz16中抑制军团菌活性物的制备方法
BR112020004149A2 (pt) * 2017-08-31 2020-09-08 Syngulon Sa métodos e composições para fabricar bacteriocinas e peptídeos antimicrobianos
US20210169922A1 (en) * 2018-05-11 2021-06-10 Marine Polymer Technologies, Inc. Use of poly-n-acetylglucosamine nanofibers for the treatment of gingival recession
BR102021021376A2 (pt) * 2021-10-25 2023-05-09 União Brasileira De Educação Católica - Ubec Composição, processo de produção da composição e uso da composição de nanofibras que compreende pva, quitosana, antibiótico e peptídeo de defesa do hospedeiro
IT202200004574A1 (it) 2022-03-10 2023-09-10 Sergio Ammendola Nanoparticelle di N-acetilglucosammina e loro applicazioni
KR20230147412A (ko) * 2022-04-14 2023-10-23 충남대학교산학협력단 miRNA 24가 봉입된 키토산 나노입자를 유효성분으로 포함하는 에드워드시엘라 피스시시다에 대한 어류용 항생 조성물
CN115671368B (zh) * 2022-10-28 2024-03-22 东华大学 一种用于生物膜清除的纳米纤维复合贴片及其制备方法

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1038367A (en) 1963-05-28 1966-08-10 Beecham Group Ltd Penicillin derivatives
US3988411A (en) 1974-02-11 1976-10-26 American Cyanamid Company Spinning and shaping poly-(N-acetyl-D-glucosamine)
US3989535A (en) 1974-02-11 1976-11-02 American Cyanamid Company Solution of poly(N-acetyl-D-glucosamine)
US4068757A (en) 1976-11-03 1978-01-17 American Cyanamid Company Chitin derived powder in sterile surgical element package
US4195175A (en) 1978-01-03 1980-03-25 Johnson Edwin L Process for the manufacture of chitosan
JPS55152705A (en) 1979-05-18 1980-11-28 Mitsubishi Rayon Co Ltd Preparation of water-soluble alkali chitin
JPS56133344A (en) 1980-03-21 1981-10-19 Kureha Chem Ind Co Ltd Novel composite material
US4378017A (en) 1980-03-21 1983-03-29 Kureha Kagaku Kogyo Kabushiki Kaisha Composite material of de-N-acetylated chitin and fibrous collagen
JPS56131639A (en) 1980-03-21 1981-10-15 Kureha Chem Ind Co Ltd Protein-chitosan composition
US4394373A (en) 1981-04-06 1983-07-19 Malette William Graham Method of achieving hemostasis
US4532134A (en) 1981-04-06 1985-07-30 Malette William Graham Method of achieving hemostasis, inhibiting fibroplasia, and promoting tissue regeneration in a tissue wound
US4470397A (en) 1981-11-11 1984-09-11 Lucas Industries Public Limited Company Fuel injection pumping apparatus
US4605623A (en) 1982-11-08 1986-08-12 Malette William Graham Method of altering growth and development and suppressing contamination microorganisms in cell or tissue culture
JPS5998660A (ja) 1982-11-26 1984-06-07 House Food Ind Co Ltd 麺類の乾燥方法
JPS59156770A (ja) 1983-02-25 1984-09-06 Canon Inc インパクト型プリンタ
JPS58220899A (ja) 1983-03-22 1983-12-22 工業技術院長 キチン系抄造体の製造方法
JPS6025003A (ja) 1983-07-20 1985-02-07 Shiro Okamura 光磁気記録装置
US4803168A (en) 1983-09-01 1989-02-07 Damon Biotech, Inc. Microencapsulation with polymers
US4749620A (en) 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
JPS60208302A (ja) 1984-03-31 1985-10-19 Unitika Ltd キチン成形体の製造方法
JPS60215003A (ja) 1984-04-10 1985-10-28 Unitika Ltd キトサン成形体の製造方法
EP0171254B1 (en) 1984-08-03 1991-06-19 Unitika Ltd. Shaped chitin body
JPH0611810B2 (ja) 1984-08-23 1994-02-16 ユニチカ株式会社 多孔性キチン成形体及びその製造方法
JPS61253065A (ja) 1985-05-02 1986-11-10 片倉チツカリン株式会社 キトサン誘導体およびコラ−ゲンの複合材の医用材料およびその製造法
US4895724A (en) 1985-06-07 1990-01-23 Pfizer Inc. Chitosan compositions for controlled and prolonged release of macromolecules
JPH0776241B2 (ja) 1986-06-06 1995-08-16 ユニオン、カーバイド、コーポレーション アミノ多糖類及びそれらの誘導体の酸による非晶出化方法
JPS62288602A (ja) 1986-06-06 1987-12-15 Agency Of Ind Science & Technol キトサン変性物粒子の製造方法
JPH0441422Y2 (es) 1986-10-17 1992-09-29
JPH0525289Y2 (es) 1987-01-21 1993-06-25
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4942129A (en) 1987-07-28 1990-07-17 Queen's University At Kingston Multiple membrane microencapsulation
US5571821A (en) 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
JPH0532702Y2 (es) 1987-10-09 1993-08-20
JP2560363B2 (ja) 1987-12-23 1996-12-04 ライオン株式会社 キチン又はキトサン類の精製法
EP0330106A1 (de) 1988-02-25 1989-08-30 Akzo Nobel N.V. Modifizierte Cellulose für biocompatible Dialysemembranen II und Verfahren zu deren Herstellung
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5008116A (en) 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
DE3903797A1 (de) 1989-02-09 1990-08-16 Hoechst Ag Verfahren zur herstellung von aktivierten chitosanen und deren verwendung bei der herstellung von chitosanderivaten
JPH0657761B2 (ja) 1989-02-27 1994-08-03 富士紡績株式会社 多孔質キトサン成形物の製造法
JPH02240101A (ja) 1989-03-14 1990-09-25 Lion Corp 硫酸化キトサン誘導体及びその製造方法
EP0390481B1 (en) 1989-03-23 1996-02-28 Sanyo Chemical Industries Ltd. Surgical adhesive sheet
IT1229167B (it) 1989-04-10 1991-07-22 Texcontor Ets Complessi del ferro o di altri metalli con derivati solfonati del chitosano
US5071977A (en) 1989-05-10 1991-12-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Plaque inhibiting oligosaccharide
AU5885690A (en) 1989-07-11 1991-01-17 Union Carbide Chemicals And Plastics Company Inc. Emulsions comprising aminopolysaccharides
US5116747A (en) 1989-08-11 1992-05-26 University Of Waterloo Immobilization of biologically active material in capsules prepared from a water-soluble polymer and chitosan acetate
DK0426368T3 (da) 1989-10-31 1995-03-13 Howmedica Præparater indeholdende chitinderivater til forebyggelse af adhæsion
US5093319A (en) 1989-10-31 1992-03-03 Pfizer Hospital Products Group, Inc. Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions
JPH064531B2 (ja) 1990-06-04 1994-01-19 アイセロ化学株式会社 大腸崩壊性硬質カプセル
DK0544000T3 (da) 1990-08-17 1997-11-03 Drug Delivery System Inst Ltd N-acetylcarboxymethylchitosanderivater og fremgangsmåde til fremstilling deraf.
DK0500885T3 (da) 1990-08-30 1997-08-25 Warner Lambert Co Formede genstande som opnået fra en termoplastisk stivelsessmelte
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
JPH04126701U (ja) 1991-05-13 1992-11-18 株式会社日立製作所 潤滑機能を有する下部軸受
US5382569A (en) 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
JPH0691819B2 (ja) 1991-05-27 1994-11-16 工業技術院長 デアセチラーゼの製造方法
JP3046099B2 (ja) 1991-06-19 2000-05-29 ユニチカ株式会社 キチン又はキトサンの綿状物
CA2072395A1 (en) 1991-07-01 1993-01-02 John T. Hunt Bicyclic endothelin analogues
JPH0525289A (ja) 1991-07-19 1993-02-02 Unitika Ltd キチン成形体の製造法
JPH0532702A (ja) 1991-08-01 1993-02-09 Unitika Ltd 細胞接着性キチン
JPH0551465A (ja) 1991-08-23 1993-03-02 Unitika Ltd 球状キチンの製造方法
US5229123A (en) 1991-10-09 1993-07-20 Hoffmann-La Roche Inc. Antifungal agents
US5219749A (en) 1991-10-09 1993-06-15 Institute For Molecular Biology & Biotechnology/Forth Process for isolating and preparing purified chitin deacetylase
CA2121129A1 (en) 1991-10-29 1993-05-13 Patrick Soon-Shiong Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
RU2125980C1 (ru) 1991-11-05 1999-02-10 Смитклайн Бичам Корпорейшн Антагонисты эндотелиновых рецепторов, фармкомпозиция, способ их получения, способ подавления эндотелиновых рецепторов
IL100096A (en) 1991-11-20 1996-03-31 Univ Ramot Method for entrapment of active materials in chitosan
US5260002A (en) 1991-12-23 1993-11-09 Vanderbilt University Method and apparatus for producing uniform polymeric spheres
DE4200080A1 (de) 1992-01-03 1993-09-30 Reinmueller Johannes Pharmazeutische Zusammensetzung zur Wund-, Narben- und Keloidbehandlung
JPH05235905A (ja) 1992-02-21 1993-09-10 Toshiba Corp Ｃｒｃ演算装置
JPH076126A (ja) 1992-02-26 1995-01-10 Nec Corp プロセッサ間バス伝送方式
US5573934A (en) 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
JPH05271094A (ja) 1992-03-26 1993-10-19 Fuji Photo Film Co Ltd カルボキシメチル化キチン誘導体を用いる癌転移抑制剤
US5550110A (en) 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
WO1994003483A1 (en) 1992-07-30 1994-02-17 Chiron Corporation Endothelin receptor-binding compounds
US5871985A (en) 1992-09-28 1999-02-16 Brown University Research Foundation Particulate non cross-linked chitosan core matrices for encapsulated cells
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
US5447505A (en) 1993-08-04 1995-09-05 Merocel Corporation Wound treatment method
JPH07102458A (ja) 1993-09-30 1995-04-18 Unitika Ltd キチンウェブ状物
US5622834A (en) 1993-12-01 1997-04-22 Marine Polymer Technologies, Inc. Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture
US5624679A (en) 1993-12-01 1997-04-29 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine biological barriers
US6743783B1 (en) 1993-12-01 2004-06-01 Marine Polymer Technologies, Inc. Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine
US5686115A (en) 1993-12-01 1997-11-11 Marine Polymer Technologies, Inc. Poly-β-1→4-N-acetylucosamine copolymer composition with collagen
US5635493A (en) 1993-12-01 1997-06-03 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine chemotherapeutics
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
US5858350A (en) 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
US5846952A (en) 1993-12-01 1998-12-08 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine drug delivery
US5811416A (en) 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
WO1996011927A1 (en) 1994-10-12 1996-04-25 Abbott Laboratories Endothelin antagonists
TW313568B (es) 1994-12-20 1997-08-21 Hoffmann La Roche
US5658943A (en) 1995-01-05 1997-08-19 Warner-Lambert Company Phenylalanine derivatives as endothelin antagonists
US5510102A (en) 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
WO1996039122A1 (en) 1995-06-06 1996-12-12 Marine Polymer Technologies, Inc. POLY-β-1→4-N-ACETYLGLUCOSAMINE
FR2736835B1 (fr) 1995-07-17 1997-10-10 Aber Technologies Pansement pour plaies chroniques, notamment escarres, en gel de chitine
US5998468A (en) 1995-08-24 1999-12-07 Warner-Lambert Company Furanone endothelin antagonists
AU2529297A (en) 1996-04-10 1997-10-29 Warner-Lambert Company Ketoacid endothelin antagonists
US5804594A (en) 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
WO1998033781A1 (en) 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
US20030060434A1 (en) 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
ZA987019B (en) 1997-08-06 1999-06-04 Focal Inc Hemostatic tissue sealants
EP0897914B1 (en) 1997-08-19 2004-05-26 F. Hoffmann-La Roche Ag Process for the preparation of 2,5-disubstitued pyridines
CA2234936C (en) 1998-04-17 2004-06-29 Glucogenics Pharmaceuticals Inc. Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
US6046179A (en) 1998-04-17 2000-04-04 Murch; Simon Composition for and treatment of inflammatory bowel disease by colon administration of N-acetylglucosamine
DE19821598A1 (de) 1998-05-14 1999-11-18 Henkel Kgaa Verfahren zum Abbau von Biopolymeren
TW585762B (en) 1999-11-11 2004-05-01 Tanabe Seiyaku Co Pharmaceutical composition for prophylaxis or treatment of inflammatory bowel diseases
US7041657B2 (en) 2001-02-12 2006-05-09 Marine Polymer Technologies Inc. Compositions and methods for modulation of vascular structure and/or function
US8741335B2 (en) 2002-06-14 2014-06-03 Hemcon Medical Technologies, Inc. Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as Chitosan
US7371403B2 (en) 2002-06-14 2008-05-13 Providence Health System-Oregon Wound dressing and method for controlling severe, life-threatening bleeding
JP2003128704A (ja) 2001-10-24 2003-05-08 Matsumoto Shika Univ キチン・キトサンの低分子化方法及び骨伝導物の製造方法
GB0126923D0 (en) 2001-11-09 2002-01-02 Procter & Gamble Chitosan compositions
WO2003041697A1 (en) 2001-11-14 2003-05-22 Ralph Ryback Method for treating autoimmune diseases
JP3947391B2 (ja) 2001-11-28 2007-07-18 独立行政法人 日本原子力研究開発機構 橋かけ構造を有するキチン誘導体及び／又はキトサン誘導体の製造方法
US7037983B2 (en) 2002-06-14 2006-05-02 Kimberly-Clark Worldwide, Inc. Methods of making functional biodegradable polymers
US20090130186A1 (en) * 2002-06-14 2009-05-21 Hemcon Medical Technologies, Inc. Wound dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan and incorporating silver nanoparticles
FR2843125B1 (fr) 2002-08-02 2012-11-16 Coletica Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs
AU2003263332A1 (en) 2002-09-11 2004-04-30 Johnson And Johnson Medical Limited Wound dressings for the treatment of wound infection
GB2393120A (en) 2002-09-18 2004-03-24 Johnson & Johnson Medical Ltd Compositions for wound treatment
US20070237812A1 (en) * 2006-04-11 2007-10-11 Tyco Healthcare Group Multi-layer wound dressings
NZ541489A (en) 2002-12-31 2011-06-30 Marinepolymer Tech Inc Topically applied vasoconstrictor for treatment in cardic catheterization complications
NZ542501A (en) 2003-02-24 2009-09-25 Marinepolymer Tech Inc Compositions comprising chitin or chitosan and use thereof
EP1673134A4 (en) 2003-09-12 2007-03-21 Marinepolymer Tech Inc RECEIVING VASCULAR ACCESS IN HEMODIALYSIS PATIENTS
WO2005027893A1 (ja) 2003-09-19 2005-03-31 Otsuka Pharmaceutical Co., Ltd. ヒトβディフェンシン分泌促進剤
RU2240830C1 (ru) 2003-12-26 2004-11-27 ФГУП Государственный научно-исследовательский институт особо чистых биопрепаратов Раневое покрытие и способ его получения
EP1722630A4 (en) 2004-01-20 2009-05-27 Richard F Harty COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
US7780873B2 (en) 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
JP2005281239A (ja) 2004-03-30 2005-10-13 Nippon Zeon Co Ltd 鶏用ｄｎａワクチン
US7704522B2 (en) 2004-09-08 2010-04-27 Clyde Morgan Topical medicament
US20060105049A1 (en) 2004-11-12 2006-05-18 Valorisation Recherche Hscm & Universite De Montreal Folic acid-chitosan-DNA nanoparticles
DE102004061406A1 (de) 2004-12-21 2006-07-06 Bayer Innovation Gmbh Infektionsresistente Polyurethanschäume, Verfahren zu ihrer Herstellung und Verwendung in antiseptisch ausgestatteten Wundauflagen
US20070036846A1 (en) * 2005-08-15 2007-02-15 Tsang Wing W M Wound dressing and method of manufacture thereof
EP1948810A4 (en) 2005-11-04 2010-06-30 Biosyntech Canada Inc COMPOSITION AND METHOD USING CHITOSAN FOR THE EFFICIENT ADMINISTRATION OF NUCLEIC ACIDS TO CELLS
US8277849B2 (en) 2006-01-19 2012-10-02 Solazyme, Inc. Microalgae-derived compositions for improving the health and appearance of skin
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
WO2008039390A2 (en) 2006-09-22 2008-04-03 Government Of The Usa., Dept. Of Health & Human Services Compositions and methods for chitosan enhanced immune response
US20120156137A1 (en) 2006-10-20 2012-06-21 Soo-Youl Kim Composition for treatment of atopic dermatitis comprising glucosamine and derivatives thereof and a method for treatment of atopic dermatitis using them
KR100882611B1 (ko) 2006-11-14 2009-02-12 주식회사 키토라이프 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법
US9855337B2 (en) 2007-01-31 2018-01-02 Alumend, Llc Biomaterials and a method for making and using the same
DK2121048T3 (en) * 2007-02-19 2015-11-23 Marinepolymer Tech Inc Hemostatic compositions and therapeutic regimens
ES2324192B1 (es) * 2008-01-30 2010-06-17 PUIG BEAUTY & FASHION GROUP, S.L. Derivados peptidicos utiles en el tratamiento, cuidado o limpieza de la piel, mucosa, cuero cabelludo o uñas.
US8436157B2 (en) 2008-03-26 2013-05-07 Tate & Lyle Technology Limited Method for the production of sucralose
NZ590466A (en) 2008-07-18 2012-08-31 Novozymes Adenium Biotech As Treatment of inflammatory diseases with mammal beta defensins
US20100086613A1 (en) 2008-10-03 2010-04-08 Chang-Jer Wu Chitosan vehicle and method for making same
US20100105139A1 (en) 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
MX342912B (es) 2010-04-15 2016-10-19 Marine Polymer Tech Inc Aplicaciones antibacterianas de nanofibras de poli-n-acetilglucosamina.
CA2833415A1 (en) 2010-05-10 2011-11-17 Corporation De L'ecole Polytechnique De Montreal Gene therapy for diabetes with chitosan-delivered plasmid encoding glucagon-like peptide 1
CA2816999A1 (en) 2010-11-06 2012-05-10 Marine Polymer Technologies, Inc. Compositions and methods for nanopolymer-based nucleic acid delivery
CN107412256A (zh) 2011-04-15 2017-12-01 海洋聚合物技术公司 用聚‑n‑乙酰基葡糖胺纳米纤维治疗疾病
US20140363673A1 (en) 2011-05-15 2014-12-11 National University Corporation Tottori University Therapeutic agent for inflammatory bowel disease
AU2014248454B2 (en) 2013-03-14 2018-11-15 Marine Polymer Technologies, Inc. Treatment of disease with poly-N-acetylglucosamine nanofibers

Also Published As

Publication number Publication date
NZ602909A (en) 2015-01-30
KR101883797B1 (ko) 2018-08-30
JP2013523898A (ja) 2013-06-17
US10561677B2 (en) 2020-02-18
JP2018203766A (ja) 2018-12-27
US20190247410A1 (en) 2019-08-15
US20130129789A1 (en) 2013-05-23
US20150140045A1 (en) 2015-05-21
IL222375A0 (en) 2012-12-31
KR20130069625A (ko) 2013-06-26
JP2016196466A (ja) 2016-11-24
EP2563371A1 (en) 2013-03-06
BR112012025844A2 (pt) 2017-07-18
EP2563371A4 (en) 2013-10-23
MX2012011816A (es) 2013-01-22
US9642871B2 (en) 2017-05-09
US8858964B2 (en) 2014-10-14
US20160235774A1 (en) 2016-08-18
CN107412772A (zh) 2017-12-01
WO2011130646A1 (en) 2011-10-20
AU2011239466A1 (en) 2012-11-01
JP6761453B2 (ja) 2020-09-23
CN103108638B (zh) 2016-11-09
NZ703163A (en) 2016-06-24
US20180099003A1 (en) 2018-04-12
JP6400628B2 (ja) 2018-10-03
AU2011239466B2 (en) 2015-01-22
CA2796068A1 (en) 2011-10-20
HK1185278A1 (zh) 2014-02-14
IL222375A (en) 2017-07-31
CA2796068C (en) 2022-07-19
CN103108638A (zh) 2013-05-15
US10206938B2 (en) 2019-02-19
US9198928B2 (en) 2015-12-01

Similar Documents

Publication Publication Date Title
MX342912B (es) Aplicaciones antibacterianas de nanofibras de poli-n-acetilglucosamina.
IL274109A (en) Staphylococcus aureus leukocyte killers, medicinal preparations, and their use
GEP20156370B (en) Fluoro-pyridinone derivatives useful as antibacterial agents
HK1225961A1 (zh) 治療或預防金黃色葡萄球菌感染以及根除或減少表面上金黃色葡萄球菌的組合物和方法
UA106743C2 (uk) Застосування цистеаміну як протимікробного агента
PH12014502397A1 (en) Pesticidal compositions and processes related thereto
PH12015501392A1 (en) Pesticidal compositions and processes related thereto
MX2018001075A (es) Agentes terapeuticos y profilacticos antibacterianos.
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
PH12013502686A1 (en) Pesticidal compositions and processes related thereto
CL2013001316A1 (es) Composicion que comprende micro-organismo probioticos no replicantes que protegen contra las infecciones del tracto respiratorio superior.
SG11201405829WA (en) Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections
MX336260B (es) Composiciones para el tratamiento de infecciones de pulmon, formuladas para ser administrables mediante aerolizacion, y que incluyen tobramicina.
PH12015501394A1 (en) Pesticidal compositions and processes related thereto
MX2011008043A (es) Derivados de actagardina.
MX2012000136A (es) Composiciones que comprenden finafloxacina y metodos para tratar infecciones oftalmicas, oticas, o nasales.
SG10201900541QA (en) Derivatives of xanthone compounds
MX2013011971A (es) Tratamiento de enfermedades con nanofibras de poli-n-acetil-glucosamina.
LT2547361T (lt) Staphylococcus aureus bakterinės vakcinos komponentai ir jų naudojimas
AU2012335397A8 (en) Novel bacteriophages
CY20142200001T2 (el) Αντιβακτηριακος παραγοντας για τη θεραπεια λοιμωδων νοσηματων βακτηριακης προελευσης
MY171941A (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
FG Grant or registration